Lupin Receives U.S. FDA Approval for Pitolisant Tablets
Global pharmaceutical company Lupin Limited has secured final approval from the U.S. Food and Drug Administration (FDA) for its Pitolisant tablets. The medication is indicated for the treatment of narcolepsy.
Lupin Limited, a pharmaceutical company, announced it has received final approval from the U.S. Food and Drug Administration (FDA) for Pitolisant tablets. The approval is for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy.
Pitolisant is described as a first-in-class treatment that targets the histamine system in the brain. It is intended to improve wakefulness in patients suffering from the condition. The FDA's decision follows the review of clinical trials assessing the drug's efficacy and safety profile.
Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, often resulting in severe EDS, cataplexy, and other symptoms. The availability of Pitolisant offers a new therapeutic option for individuals diagnosed with narcolepsy in the United States.
Lupin, headquartered in India, is a global pharmaceutical player with operations across various therapeutic areas. The company's portfolio includes treatments for respiratory, cardiovascular, and central nervous system disorders, among others.